| Title: |
Abstract 4145932: Real World Data From A Nationwide Survey: Current Approaches Post Acute Coronary Syndromes By Cardiologists |
| Authors: |
SABOURET, Pierre; Santos, Raul; Sharareh, Ali; garban, thierry; Cohen, Serge; Parrens, Eric; Villaceque, Marc; Guedjmeynier, Dominique; Lequeux, Benoit; Hoffman, Olivier; Dib, Jean-Claude; Durand, Philippe; Bernardi, Marco; Spadafora, Luigi; Asher, Elad; Bhatt, Deepak; Biondi-Zoccai, Giuseppe; Banach, Maciej; Amara, Walid; Schiele, Francois; Lellouche, Nicolas; Dievart, Francois |
| Source: |
Circulation ; volume 150, issue Suppl_1 ; ISSN 0009-7322 1524-4539 |
| Publisher Information: |
Ovid Technologies (Wolters Kluwer Health) |
| Publication Year: |
2024 |
| Description: |
Background: A new ESC guidelines in 2023, the International Lipid Expert Panel (ILEP) 2021 recommendations, and a subsequent statement by EAS have been published based on recent advances in lipid lowering treatments. However, real world data are lacking regarding the implementation among the community of French cardiologists. Objective: To determine the current approach and therapeutic strategies concerning lipid lowering treatments post-acute coronary syndromes in France. Methods: This national survey was performed during October and November 2023 in France with an online questionnaire on the websites of 2 national French Societies of Cardiologists. Four mailings were sent to cardiologists to invite them to answer to the questionnaire. A total of 400 answers of cardiologists were collected during this 2-month period. Results: For ASCVD patients, cardiologists agreed with an LDL-C goal below 55 mg/dL (1.4 mmol/L) in 69%, below 70 mg/dL (1.8 mmol/L) in 16.5%, and 14.5% between 70 mg/dL and 100 mg/dL (1.8-2.5 mmol/L). An upfront lipid lowering combination strategy using fixed dose combination (FDC) of statins and ezetimibe was prescribed in less than 5% of patients, whereas high-intensity statins were prescribed in more than 90% of patients. No significant differences were observed in terms of sex of patients, geographical area, or strategies followed by male and female cardiologists ( p > 0.05). A combination of statins and ezetimibe was prescribed only for a minority of patients, especially as an early upfront strategy. The use of PCSK9i remains marginal and the interval between the ACS and initiation of these medicines remains high. Conclusion: In this contemporary national survey, we report an excellent agreement of lipid goals in secondary prevention by cardiologists. Despite the declared consensus recommending a low LDL-C target in ACS patients, lipid lowering strategies are suboptimal, mainly consisting of high intensity statins. The lack of recommended use of ezetimibe and PCSK9i to lower LDL-C levels ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1161/circ.150.suppl_1.4145932 |
| Availability: |
https://doi.org/10.1161/circ.150.suppl_1.4145932; https://journals.lww.com/10.1161/circ.150.suppl_1.4145932 |
| Accession Number: |
edsbas.116CAA3C |
| Database: |
BASE |